RESEARCH TRIANGLE PARK, N.C., Jan. 9 /PRNewswire/ -- Interventional Rhythm Management, Inc. (IRM), a privately held company with a disruptive technology for the treatment of abnormal heart rhythms, today announced the appointment of veteran financial executive Benny Ward as Vice President and Chief Financial Officer, effective January 10. Mr. Ward has more than 15 years of experience in financial operations and management.
Mr. Ward, 42, served for more than nine years as Chief Financial Officer of Closure Medical Corporation, a publicly-traded medical device developer and manufacturer located in Raleigh, N.C. that was acquired by Johnson & Johnson in June 2005.
“We are privileged to attract a veteran medical device CFO like Benny to our organization,” said IRM President and Chief Executive Officer Daniel A. Pelak, who worked with Mr. Ward at Closure. “He brings a wealth of experience and solid credentials to our team. His leadership, professional acumen and relationships with members of the financial community make him an ideal fit for the position.
“Mr. Ward joined Closure in 1996 as its Controller and was appointed CFO in March 2000. He was a key member of management from Closure’s successful Initial Public Offering through the sale of the business last year. Closure was a leader in developing and manufacturing biomaterials for wound closure with end-user revenues approximating $125 million.
Prior to joining Closure, Mr. Ward spent three years as an auditor with Price Waterhouse. A Certified Public Accountant, Mr. Ward has a bachelor’s degree in Accounting and a bachelor’s degree in Political Science from East Carolina University.
About Interventional Rhythm Management, Inc.
Interventional Rhythm Management, Inc., an early stage company, has created a disruptive technology platform for cardiac rhythm management (CRM) devices utilizing interventional technology. IRM’s mission is to better serve cardiac arrhythmia patients by developing cardiac devices that will offer reduced implantation time, simplified implantation procedure, increased patient comfort, and expanded access to therapy. Analysts estimate the worldwide CRM market, comprised of pacemakers, implantable and external defibrillators, to exceed $8 billion in 2005.
IRM was founded in 2003 to focus on the management of patients with arrhythmias, or abnormal heart rhythms. To date, IRM has raised $35.2 million through two rounds of private financings; investors included Delphi Ventures, Frazier Healthcare Ventures, and Johnson & Johnson Development Corporation.
Contact: Len Hall
Allen & Caron Inc.
(949) 474-4300
Interventional Rhythm Management, Inc.
CONTACT: Len Hall of Allen & Caron Inc., +1-949-474-4300, forInterventional Rhythm Management, Inc.
